Positive Phase 1/2 Clinical Trial Results of Genethon ’s Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease, Published in The New England Journal of Medicine
PARIS--(BUSINESS WIRE) August 22, 2023 --Genethon, a pioneer and leader in gene therapy research and development for rare genetic diseases, announced today positive Phase 1/2 clinical trial results of its gene therapy, GNT-0003, for Crigler-Najjar...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Gene Therapy | Genetics | Liver | Liver Disease | Pharmaceuticals | Urology & Nephrology